TD Asset Management
CYCN icon

TD Asset Management’s Cyclerion Therapeutics CYCN Stock Holding History

TD Asset Management’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,975
Closed -$240K – 1444
2020
Q3 		$240K Buy
1,975
+708
+56% +$81K ﹤0.01% 1326
2020
Q2 		$150K Buy
1,267
+17
+1% +$1.42K ﹤0.01% 1300
2020
Q1 		$66K Buy
+1,250
New +$89.2K ﹤0.01% 1353

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TD Asset Management's CYCN Position: Q4 2020 in Review

TD Asset Management sold out of Cyclerion Therapeutics (CYCN) in Q4 2020, closing a stake of 1,975 shares — an estimated $240K sold.

TD Asset Management first reported a position in CYCN in Q1 2020 and held it in 3 quarters. The position peaked at $240K in Q3 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q4 2020.

  • TD Asset Management reported no remaining Cyclerion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • TD Asset Management sold 1,975 Cyclerion Therapeutics shares in Q4 2020, an estimated $240K.
  • TD Asset Management first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 3 quarters.
  • TD Asset Management's Cyclerion Therapeutics position peaked at $240K in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2020.

Based on TD Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.